Turn ESMO data into business-critical insights. 30 high-prescribing oncologists analyze 10 Cervical Cancer abstracts to help you prepare for what’s next. Take the guesswork out of understanding changes in prescribing behavior for: anlotinib, apatinib, balstilimab, BYL719 (alpelisib), camrelizumab, carboplatin, cemiplimab, durvalumab, endostar, metronomic oral vinorelbine, nab-paclitaxel, pembrolizumab, sintilimab, tisotumab vedotin, tremelimumab and zalifrelimab among others. Get your 65+ slide report.

Cervical Cancer Report ESMO 2021

European Society for Medical Oncology

Virtual Meeting
Sep 16 to Sep 21

Share: